Compare Invitation Homes Inc. Common Stock (INVH) vs Medline Inc. Class A Common Stock (MDLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invitation Homes Inc. Common Stock vs Medline Inc. Class A Common Stock — how do they compare? Invitation Homes Inc. Common Stock trades at $26.54 (market cap $15.70B), while Medline Inc. Class A Common Stock trades at $35.86 (market cap $31.32B). The key difference: Medline Inc. Class A Common Stock is the larger of the two by market cap, and Invitation Homes Inc. Common Stock pays a 4.51% dividend while Medline Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invitation Homes Inc. Common Stock for 0 Days and Medline Inc. Class A Common Stock for 6 Days on average.
| INVH | MDLN | |
|---|---|---|
Market Cap | $15.70B | $31.32B |
Volume | 4,685,416 | 4,364,703 |
Sector | Real Estate | Health |
52-Week High | $30.59 | $49.99 |
52-Week Low | $24.39 | $31.64 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $24.16B | $41.28B |
Dividend Yield | 4.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
Medline (MDLN) trades at $35.70, down 0.17% with a bullish technical outlook despite recent volatility. The company shows strong revenue growth with $28.43B in 2025 and improved earnings beats in Q1-Q2 2026. However, multiple securities fraud investigations related to product quality issues and a 13% stock drop in October 2026 create significant headwinds. Analyst consensus remains strongly bullish with 88% buy ratings and a $44.11 price target, representing 23.6% upside potential from current levels.
MDLN presents a high-risk, high-reward opportunity with strong fundamentals offset by legal uncertainties. The stock's valuation appears reasonable with P/E of 44.66 and P/S of 1.05, while technical indicators suggest near-term support at $35. Key risks include ongoing fraud investigations and potential legal liabilities that could impact future performance despite positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invitation Homes Inc. Common Stock
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →
